Author: Godwin, Kerry ; Saeed, Mohsan ; Amcheslavsky, Alla ; Wang, Yang ; Close, Brianna J ; Klempner, Mark S ; Coombes, Naomi ; Schneider, Ryan ; Hou, Shurong ; Ganesa, Chandrashekar ; Li, Qi ; Conway, Hasahn L ; Kurt Yilmaz, Nese ; Carroll, Miles W ; Schiffer, Celia A ; Chen, Da-Yuan ; Buttigieg, Karen R ; Ramchetty, Anudeep S ; Ejemel, Monir ; Schiller, Zachary A ; Wallace, Aaron ; Toomey, Jacqueline R ; Tree, Julia A ; Cavacini, Lisa A ; Elmore, Michael J

AbstractCOVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.

IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity

Author: Hou, Shurong ; Wallace, Aaron L. ; Cavacini, Lisa A. ; Conway, Hasahn L. ; Ejemel, Monir ; Close, Brianna J. ; Mohsan, Saeed ; Klempner, Mark S. ; Yilmaz, Nese Kurt ; Schiffer, Celia A. ; Amcheslavsky, Alla ; Wang, Yang ; Li, Qi ; Schiller, Zachary A. ; Toomey, Jacqueline R. ; Schneider, Ryan ; Chen, Da-Yuan

SummaryCOVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.

100 Deals associated with MAb-362 (Masssachusetts Biologic Laboratories)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	US	MassBiologics	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

MAb-362 (Masssachusetts Biologic Laboratories)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation